Presentations and Publications

You are here: Home | Newsroom | Presentations and Publications

Qnexa	EASD	EASD Presentation in Vienna October 2, 2009
Qnexa		Qnexa Phase 3 Results Conference Call September 9, 2009
Qnexa	ADA	Weight Loss with VI-0521 Stops Progression Toward Type 2 Diabetes in Obese Non-diabetic Subjects June, 2009
Qnexa	ADA	Can Weight Loss Treat Diabetes? Results of One-Year of Treatment with VI-0521 in Obese Type 2 Diabetics June, 2009
Qnexa	NAASO	Long-Term Follow-Up of Phentermine with Topiramate for Obesity in Clinical Practice
Qnexa	NAASO	Changes in Weight and Quality of Life in Obese Adults Treated with Topiramate Plus Phentermine
Qnexa	ADA	The Weight Effects of VI-0521 in Type 2 Diabetes
Qnexa	ADA	Effect of VI-0521 (Phentermine and Topiramate) in Type 2 Diabetes (Abstract)
Avanafil	SMSNA	Safety and Efficacy of Avanafil, A new PDE5 Inhibitor for Treating Erectile Dysfunction
Avanafil	SMSNA	Hemodynamic Effects of Co-Administration of Avanafil and Glyceryl Trinitrate
Avanafil	SMSNA	Pharacokinetics of Avanafil, a New PDE5 Inhibitor Being Developed for Treating Erectile Dysfunction
Luramist	MDTS	Efficacy and Safety of the Testosterone (T) Metered-Dose Transdermal Spray in Premenopausal Women: a Placebo-Controlled, Randomized, Parallel, Dose-Ranging Study